Clinical Trial Update: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3b study assessing safety and efficacy of apremilast for moderate to severe plaque psoriasis and psoriatic arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis, Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-08-04